Want to see GOVX full AI Analyst Report?
Top Page
GeoVax Labs
(NASDAQ:GOVX)
Select Model
Select Model
Rating:39Underperform
Price Target:
$0.72
▼(-1.78% Downside)
Action:Downgraded
Date:07/28/26
The score is driven primarily by very weak financial performance (zero TTM revenue, large ongoing losses, and sustained cash burn) and a technically bearish trend with the stock below all major moving averages. Valuation provides limited support due to negative earnings and no dividend yield, while the Nasdaq noncompliance notice adds meaningful downside risk via potential listing uncertainty.
Positive Factors
Proprietary vaccine platform and diversified clinical pipeline
GeoVax’s proprietary vaccine technology underpins multiple clinical programs across infectious disease and oncology, providing a durable R&D platform and IP estate. A diversified pipeline with distinct regulatory pathways (including an expedited Phase 3 path for GEO-MVA) supports multiple long-term value-creation channels and partnership opportunities.
Negative Factors
Zero TTM revenue and persistent negative cash flow
The company generates no material recurring revenue and free cash flow is strongly negative, meaning development expenses translate into real cash burn. Sustained negative cash flow forces ongoing funding needs, increases dilution risk over time, and constrains ability to scale operations or invest without external capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary vaccine platform and diversified clinical pipeline
GeoVax’s proprietary vaccine technology underpins multiple clinical programs across infectious disease and oncology, providing a durable R&D platform and IP estate. A diversified pipeline with distinct regulatory pathways (including an expedited Phase 3 path for GEO-MVA) supports multiple long-term value-creation channels and partnership opportunities.
Read all positive factors
GeoVax Labs (GOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.02M
Dividend YieldN/A
Average Volume (3M)453.76K
Price to Earnings (P/E)―
Beta (1Y)3.54
Revenue Growth-100.00%
EPS Growth77.63%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,369,243
10 Day Avg. Volume297,748
30 Day Avg. Volume453,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.07
Price to Sales (P/S)1.65
P/FCF Ratio-0.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside1269.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GeoVax Labs Business Overview & Revenue Model
Company Description
GeoVax Labs, Inc. (GOVX) is a biotechnology company focused on the research and development of vaccines and immunotherapies for infectious diseases and certain cancers. The company’s core work centers on developing product candidates using its pro...
How the Company Makes Money
GeoVax is a clinical-stage biotechnology company and, based on publicly available information, it has historically not generated material recurring revenue from product sales because its vaccine candidates have been in research and development rat...
GeoVax Labs Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
32
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 2.49M | 3.95M | 0.00 | 81.53K | 385.50K |
| Gross Profit | -8.91M | -15.63M | 3.86M | -20.72M | -9.04M | -15.17M |
| EBITDA | -20.56M | -21.40M | -24.88M | -25.89M | -13.96M | -18.53M |
| Net Income | -20.43M | -21.46M | -24.99M | -25.97M | -14.02M | -18.57M |
Balance Sheet | ||||||
| Total Assets | 4.64M | 6.34M | 8.16M | 9.28M | 31.35M | 11.80M |
| Cash, Cash Equivalents and Short-Term Investments | 3.14M | 3.09M | 5.51M | 6.45M | 27.61M | 11.42M |
| Total Debt | 323.14K | 843.17K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.88M | 2.52M | 3.11M | 3.52M | 4.75M | 7.43M |
| Stockholders Equity | 1.76M | 3.83M | 5.05M | 5.76M | 26.60M | 4.36M |
Cash Flow | ||||||
| Free Cash Flow | -18.37M | -21.50M | -24.70M | -25.22M | -19.16M | -11.24M |
| Operating Cash Flow | -18.37M | -21.47M | -24.68M | -25.17M | -19.03M | -11.20M |
| Investing Cash Flow | 0.00 | -27.61K | -20.65K | -48.95K | -134.26K | -47.72K |
| Financing Cash Flow | 18.42M | 19.08M | 23.75M | 4.06M | 35.35M | 12.78M |
GeoVax Labs Risk Analysis
GeoVax Labs disclosed 31 risk factors in its most recent earnings report. GeoVax Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GeoVax Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $49.23M | -3.81 | -82.34% | ― | ― | 16.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.69M | -1.46 | -47.86% | ― | -93.71% | 23.89% | |
46 Neutral | $22.17M | -0.61 | -202.41% | ― | -45.35% | 58.32% | |
45 Neutral | $17.48M | -1.08 | -66.69% | ― | -45.52% | -94.82% | |
41 Neutral | $8.14M | -0.19 | -246.04% | ― | ― | 54.48% | |
39 Underperform | $5.02M | -0.05 | -709.51% | ― | -100.00% | 77.63% |
* Healthcare Sector Average
GOVX
GeoVax Labs
0.76
-17.47
-95.82%
BLRX
Bioline RX Ltd Sponsored ADR
2.76
-1.13
-29.05%
SNGX
Soligenix
0.38
-2.60
-87.35%
LPCN
Lipocine
2.13
-0.95
-30.84%
EDSA
Edesa Biotech
5.36
3.10
137.17%
LGVN
Longeveron
0.74
-0.81
-52.13%
GeoVax Labs Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
GeoVax Labs Faces Nasdaq Noncompliance and Listing Risk
Negative
Jul 10, 2026
On July 7, 2026, GeoVax Labs received notice from Nasdaq that it is not in compliance with the $2.5 million minimum stockholders’ equity requirement and does not meet alternative criteria for continued listing under the applicable Nasdaq rul...
Executive/Board ChangesPrivate Placements and FinancingShareholder Meetings
GeoVax Shareholders Back Board, Auditor and Warrant Issuances
Neutral
Jun 17, 2026
GeoVax Labs held its annual meeting of stockholders on June 17, 2026, with investors electing a seven-member board of directors and ratifying Wipfli LLP as the independent auditor for the fiscal year ending December 31, 2026. Shareholders also gav...
Business Operations and StrategyPrivate Placements and Financing
GeoVax Raises $3 Million via Private Placement Financing
Neutral
May 19, 2026
GeoVax Labs, Inc., a clinical-stage biotech focused on vaccines and immunotherapies for infectious diseases and solid tumors, is advancing its GEO-MVA mpox and smallpox vaccine toward an expedited Phase 3 trial, while progressing its Gedeptin gene...
Private Placements and Financing
GeoVax Labs Announces Warrant Inducement and Financing Move
Neutral
May 7, 2026
On May 7, 2026, GeoVax Labs entered into a warrant inducement agreement with existing institutional investors, prompting the immediate cash exercise of warrants for 501,144 shares of common stock, expected to generate about $595,000 in gross proce...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.